Fairvalue-Calculator Fairvalue-Calculator
EN DE

Novacyt S.A (ALNOV) Fair Value & Analysis

Healthcare · FR · Market cap €42.7M

Price€0.3900
Fair Value€0.1500
Upside-61.5%
Quality95/100
Evidence: Low Range €0.1000 – €0.1900

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Novacyt S.A (ALNOV) currently trades at €0.3900, while our model-based Fair Value estimate is €0.1500 — implying the stock looks roughly 61.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -95% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Novacyt S.A (ALNOV) undervalued?
As of Jun 25, 2026, our model estimates a fair value of €0.1500 versus a price of €0.3900 — about −62% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALNOV?
Our 21-model fair value for Novacyt S.A is €0.1500 (as of Jun 25, 2026), built from audited fundamentals. The current price is €0.3900.
What is the quality score of ALNOV?
Novacyt S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.